Related Experiment Video
Updated: Aug 11, 2026

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
Published on: June 29, 2013
Medical management of intermittent claudication
Kevin Casey1, Britt H Tonnessen, W Charles Sternbergh
1Department of Vascular Surgery, Ochsner Clinic Foundation, New Orleans, LA 70121, USA.
Insights
Intermittent claudication (IC) symptoms often prompt medical visits, but few cases progress to severe outcomes. Managing co-morbidities and risk factors is crucial for these patients.
Area of Science:
- Vascular Medicine
- Cardiology
- Peripheral Artery Disease
Background:
- Intermittent claudication (IC) is a common symptom prompting medical evaluation.
- A minority of patients with IC experience limb-threatening ischemia or severe lifestyle limitations.
- Patients with IC have a high prevalence of concurrent cardiovascular and cerebrovascular diseases.
Purpose of the Study:
- To review the clinical presentation and management of intermittent claudication.
- To highlight the importance of assessing and managing co-morbidities in IC patients.
- To discuss the role of pharmacotherapy in alleviating IC symptoms.
Main Methods:
- Literature review of studies on intermittent claudication.
- Analysis of risk factors and co-morbidities associated with IC.
- Evaluation of pharmacological interventions for IC symptom management.
Main Results:
- Most IC cases do not progress to severe limb ischemia.
- Cardiovascular and cerebrovascular disease assessment and risk factor control are vital.
- While no single drug cures IC, some therapies can reduce symptoms as adjuvant treatment.
Conclusions:
- Intermittent claudication management requires a comprehensive approach.
- Addressing co-morbidities significantly mitigates cardiovascular risk in IC patients.
- Pharmacological agents can serve as valuable adjuncts for symptom relief in IC.
Abstract:
The symptoms of intermittent claudication (IC) lead sufferers to seek medical attention, potentially leading to substantial workup and invasive testing. However, only a minority of people with IC develop limb-threatening ischemia or symptoms of significant lifestyle-limiting claudication. Patients with IC have a substantial risk of concomitant cardiovascular and cerebrovascular disease. Assessment of co-morbidities and control of risk factors reduce the cardiovascular risk of these patients. A multitude of drugs have been developed and tested in numerous trials for the symptoms of IC. Although no drug alone offers a "cure" to IC, some are used as adjuvant therapy to reduce claudication symptoms.
More Related Videos
Related Concept Videos
Angina IV: Management
Atherosclerosis III: Management
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease IV: Nursing Management
Peripheral Artery Disease V: Postoperative Nursing Management

